News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,025 Results
Type
Article (14305)
Company Profile (281)
Press Release (254439)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79780)
Career Advice (161)
Deals (13255)
Drug Delivery (36)
Drug Development (50501)
Employer Resources (33)
FDA (5742)
Job Trends (5155)
News (144777)
Policy (10052)
Tag
Academia (919)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21733)
ALS (64)
Alzheimer's disease (848)
Antibody-drug conjugate (ADC) (100)
Approvals (5769)
Artificial intelligence (125)
Autoimmune disease (18)
Automation (5)
Bankruptcy (108)
Best Places to Work (4576)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (156)
Cancer (1486)
Cardiovascular disease (117)
Career advice (142)
Career pathing (3)
CAR-T (119)
Cell therapy (334)
Cervical cancer (8)
Clinical research (41130)
Collaboration (543)
Compensation (263)
Complete response letters (13)
COVID-19 (1035)
CRISPR (42)
C-suite (165)
Cystic fibrosis (76)
Data (1531)
Decentralized trials (1)
Denatured (11)
Depression (31)
Diabetes (139)
Diagnostics (1301)
Digital health (3)
Diversity (3)
Diversity, equity & inclusion (10)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29890)
Editorial (18)
Employer branding (4)
Employer resources (32)
Events (48701)
Executive appointments (464)
FDA (6449)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (498)
Gene editing (97)
Generative AI (10)
Gene therapy (255)
GLP-1 (367)
Government (1086)
Grass and pollen (2)
Guidances (27)
Healthcare (6612)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1100)
Inflammatory bowel disease (115)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (22)
IPO (7279)
IRA (11)
Job creations (865)
Job search strategy (133)
Kidney cancer (7)
Labor market (5)
Layoffs (212)
Leadership (4)
Legal (1390)
Liver cancer (33)
Lung cancer (205)
Lymphoma (102)
Machine learning (3)
Management (8)
Manufacturing (141)
MASH (54)
Medical device (2610)
Medtech (2611)
Mergers & acquisitions (6305)
Metabolic disorders (391)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (68)
Neuropsychiatric disorders (25)
Neuroscience (1260)
NextGen: Class of 2025 (2035)
Non-profit (863)
Now hiring (21)
Obesity (194)
Opinion (102)
Ovarian cancer (63)
Pain (44)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (130)
Patient recruitment (79)
Peanut (35)
People (25786)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14519)
Phase II (19127)
Phase III (12098)
Pipeline (818)
Policy (47)
Postmarket research (858)
Preclinical (6141)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1426)
Recruiting (14)
Regulatory (8659)
Reports (15)
Research institute (942)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (61)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1978)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (215)
Venture capitalists (32)
Weight loss (110)
Women's health (16)
Worklife (2)
Date
Last 7 days (519)
Last 30 days (1439)
Last 365 days (19455)
2025 (6363)
2024 (20565)
2023 (22428)
2022 (26906)
2021 (27923)
2020 (23473)
2019 (16300)
2018 (11809)
2017 (13774)
2016 (11860)
2015 (14367)
2014 (10420)
2013 (7499)
2012 (7575)
2011 (7644)
2010 (7446)
Location
Africa (152)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17336)
Australia (2940)
California (3890)
Canada (1147)
China (363)
Colorado (149)
Connecticut (152)
Delaware (103)
Europe (37312)
Florida (468)
Georgia (117)
Idaho (16)
Illinois (234)
India (12)
Indiana (92)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (478)
Massachusetts (3097)
Michigan (70)
Minnesota (145)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (971)
New Mexico (12)
New York (1050)
North Carolina (558)
North Dakota (5)
Northern California (1717)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (743)
Puerto Rico (6)
Rhode Island (19)
South America (211)
South Carolina (4)
Southern California (1498)
Tennessee (25)
Texas (450)
United States (13344)
Utah (53)
Virginia (81)
Washington D.C. (31)
Washington State (352)
Wisconsin (15)
269,025 Results for "accent therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025
April 28, 2025
·
6 min read
Press Releases
Accent Therapeutics to Present Data on Lead Programs ATX-559 and ATX-295 at the 2025 American Association for Cancer Research Annual Meeting
March 25, 2025
·
5 min read
Genetown
Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting
Accent Therapeutics presents advances in cancer targeting at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.
April 8, 2024
·
6 min read
Genetown
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million Series C financing.
January 23, 2024
·
5 min read
Press Releases
Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor
October 24, 2024
·
5 min read
Genetown
Accent Therapeutics to Present Data Supporting DHX9 and KIF18A as Compelling Therapeutic Targets at American Association for Cancer Research (AACR) Annual Meeting 2024
Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced four upcoming presentations and posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.
March 21, 2024
·
4 min read
Business
Accent Therapeutics Bolsters Leadership Team with Key Executive Hires
Accent Therapeutics today announced the appointments of Jason Sager, M.D. as Chief Medical Officer, Steven Mennen, Ph.D., as Vice President of Pre-Clinical Development and Stuart Ince, Ph.D. as Vice President of Program Leadership.
September 21, 2023
·
5 min read
Genetown
Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium
Accent Therapeutics today announced it will present data unveiling a novel, previously undisclosed program in two poster presentations at the 35th AACR-NCI-EORTC Symposium held October 11-15, 2023 in Boston, Massachusetts.
October 10, 2023
·
6 min read
Genetown
Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023
Accent Therapeutics presented data supporting DHX9 inhibition as a novel cancer treatment approach at the American Association for Cancer Research Annual Meeting 2023 in Orlando, Florida.
April 16, 2023
·
4 min read
Genetown
Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023
Accent Therapeutics today announced an upcoming presentation introducing DHX9 inhibition as a novel cancer treatment approach at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.
April 6, 2023
·
2 min read
1 of 26,903
Next
